13:22 uur 31-05-2017

Chiltern verwerft Japanse CRO Integrated Development Associates Co. Ltd.

LONDEN & WILMINGTON, N.C. & TOKIO–(BUSINESS WIRE)– Chiltern, een toonaangevende organisatie voor uitbesteed onderzoek (CRO), heeft Integrated Development Associates Co. Ltd. (IDA) aangekocht. Deze CRO specialiseert zich in de integratie van Japan en Azië in mondiale programma’s voor medicijnontwikkeling.

IDA – dat personeel in Japan, Korea en Zuidoost-Azië heeft – is een expert in het opzetten van trajecten voor wettelijke goedkeuring en medicijnontwikkeling in Japan. Het bedrijf organiseert ook klinisch-wetenschappelijke onderzoeken in meerdere Aziatische landen. Dit is noodzakelijk om aan mondiale en Japanse wettelijke normen te voldoen. De ervaring van IDA in uiteenlopende therapeutische vakgebieden, lokale kennis en contacten stellen Chiltern in staat optimale werkmethodes aan te bieden voor aansluiting van Japan en Azië bij mondiale medicijnontwikkelingsprojecten. De overname biedt Japanse bedrijven bovendien kansen op een grotere markt, dankzij de internationale expertise en contacten van Chiltern.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Contacts

SCORR Marketing for Chiltern
Lea Studer, +1-308-237-5567
lea@scorrmarketing.com

 

 

Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.

LONDON & WILMINGTON, N.C. & TOKYO–(BUSINESS WIRE)– Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections.

“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”

IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger, will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.

To learn more about Chiltern’s global clinical development services, visit Chiltern.com.

About Chiltern
Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You ®.

SCORR Marketing for Chiltern
Lea Studer, +1-308-237-5567
lea@scorrmarketing.com
Check out our twitter: @NewsNovumpr